Stocks · News reference
Oculis released new Phase 2 ACUITY trial biomarker data, which further supports the neuroprotective potential of its drug candidate, Privosegtor, for treating optic neuritis and other neuro-axonal diseases.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Oculis Holding AG announced it will present data on its neuroprotective candidate, Privosegtor, and its ongoing PIONEER clinical program at the upcoming APOIS Congress and CNS Summit.
Oculis is scheduled to release its financial results for the quarter ended September 30, 2026, on November 5, 2026.
Oculis announced it will present new biomarker data from its Phase 2 ACUITY trial of Privosegtor at the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto on October 21-23, 2026. The presentation will highlight plasma NfL and GFAP biomarker analyses demonstrating neuroprotective potential in acute optic neuritis patients. Privosegtor has received FDA Breakthrough Therapy and EMA PRIME designations, with the company planning registrational trials through its PIONEER program.